Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
Recent Articles
Oral Apixaban Noninferior to Subcutaneous Dalteparin for Preventing Recurrent Cancer-Associated VTE
In patients with cancer-associated venous thromboembolism (VTE), treatment with oral apixaban was noninferior to subcutaneous dalteparin for the prevention of recurrent VTE, according to...
July 2020 Volume 6 Issue 8
This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.
How I Treat in Brief: Anticoagulation in Patients With Obesity
This month, Tzu-Fei Wang, MD, and Marc Carrier, MD, MSc, reviewed anticoagulation strategies for patients who are obese and therefore at risk of venous thromboembolism, atrial...
Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma
The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple myeloma (MM). Daratumumab was...
You Make the Call: Should this patient with DLBCL receive rituximab maintenance after R-CHOP?
This month Ann S. LaCasce, MD, MMSc, discusses whether a patient with high-risk DLBCL should receive rituximab maintenance after R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride,...
Current Issue
July 2020 Volume 6 Issue 8
This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.
